Literature DB >> 2526195

Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon.

T Bieber1, A Rieger, C Neuchrist, J C Prinz, E P Rieber, G Boltz-Nitulescu, O Scheiner, D Kraft, J Ring, G Stingl.   

Abstract

Human rIL-4 and human rIFN-gamma are able to induce the expression of the low affinity receptor for IgE (Fc epsilon R2/CD23) on normal human epidermal Langerhans cells, whereas IL-2 and PMA have no effect. A synergistic effect is observed when both cytokines are combined. These receptors are synthesized de novo by the LC since cycloheximide completely inhibits the appearance of Fc epsilon R2/CD23. Fc epsilon R2/CD23+ LC may have a major role in the pathogenesis of atopic eczema, as well as in the regulation of IgE synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526195      PMCID: PMC2189378          DOI: 10.1084/jem.170.1.309

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on the expression of Fc epsilon receptors on human B and T cells.

Authors:  M Suemura; H Kikutani; E L Barsumian; Y Hattori; S Kishimoto; R Sato; A Maeda; H Nakamura; H Owaki; R R Hardy
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

2.  Regulation of Fc epsilon R2/CD23 gene expression by cytokines and specific ligands (IgE and anti-Fc epsilon R2 monoclonal antibody). Variable regulation depending on the cell types.

Authors:  T Kawabe; M Takami; M Hosoda; Y Maeda; S Sato; M Mayumi; H Mikawa; K Arai; J Yodoi
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

3.  Regulation of Fc epsilon receptor expression on a human monoblast cell line U937.

Authors:  M Mayumi; T Kawabe; K M Kim; T Heike; K Katamura; J Yodoi; H Mikawa
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

Review 4.  Interleukin 1 and other human keratinocyte cytokines: molecular and functional characterization.

Authors:  T S Kupper
Journal:  Adv Dermatol       Date:  1988

5.  Direct monoclonal antibody rosetting. An effective method for weak antigen detection and large scale separation of human mononuclear cells.

Authors:  M Wilhelm; H Pechumer; G Rank; E Kopp; G Riethmüller; E P Rieber
Journal:  J Immunol Methods       Date:  1986-06-10       Impact factor: 2.303

Review 6.  Structure and function of Fc receptors for IgE on lymphocytes, monocytes, and macrophages.

Authors:  H L Spiegelberg
Journal:  Adv Immunol       Date:  1984       Impact factor: 3.543

7.  Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression.

Authors:  A Yokota; H Kikutani; T Tanaka; R Sato; E L Barsumian; M Suemura; T Kishimoto
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

8.  Associated expression of CD1 antigen and Fc receptor for IgE on epidermal Langerhans cells from patients with atopic dermatitis.

Authors:  C Bruynzeel-Koomen; E M van der Donk; P L Bruynzeel; M Capron; G C de Gast; G C Mudde
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

9.  The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis.

Authors:  C Bruynzeel-Koomen; D F van Wichen; J Toonstra; L Berrens; P L Bruynzeel
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

10.  Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes.

Authors:  T Defrance; J P Aubry; F Rousset; B Vanbervliet; J Y Bonnefoy; N Arai; Y Takebe; T Yokota; F Lee; K Arai
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

View more
  27 in total

1.  A microfilament formation inhibitor, cytochalasin strongly enhances the low-affinity Fc epsilon receptor II (CD23) expression on the human monocyte-like cell line, U937.

Authors:  N Ikewaki; H Tamauchi; A Yamada; M Aoki; R Yamamoto; A Sawada; H Inoko
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Increased number of IgE positive Langerhans cells in the conjunctiva of patients with atopic dermatitis.

Authors:  A Yoshida; S Imayama; S Sugai; Y Kawano; T Ishibashi
Journal:  Br J Ophthalmol       Date:  1997-05       Impact factor: 4.638

3.  Pattern of cytokine receptors expressed by human dendritic cells migrated from dermal explants.

Authors:  A T Larregina; A E Morelli; E Kolkowski; N Sanjuan; M E Barboza; L Fainboim
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 4.  Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells.

Authors:  M B Teunissen
Journal:  Histochem J       Date:  1992-10

Review 5.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

6.  Priming the macrophage respiratory burst with IL-4: enhancement with TNF-alpha but inhibition by IFN-gamma.

Authors:  W A Phillips; M Croatto; J A Hamilton
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

7.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

Authors:  S Hunot; N Dugas; B Faucheux; A Hartmann; M Tardieu; P Debré; Y Agid; B Dugas; E C Hirsch
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 8.  [Atopic patch test. Atopic eczema and allergy].

Authors:  U Darsow; J Ring
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

9.  Epidermal keratinocyte-derived basophil promoting activity. Role of interleukin 3 and soluble CD23.

Authors:  A H Dalloul; M Arock; C Fourcade; J Y Béranger; P Jaffray; P Debré; M D Mossalayi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  CD23 antigen regulation and signaling in chronic lymphocytic leukemia.

Authors:  S Fournier; G Delespesse; M Rubio; G Biron; M Sarfati
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.